Following the generation of successful results with the University of Michigan through the ACE program, Predictive Oncology is now actively calling for submissions for a new cohort of compounds to be tested in Q4 2025.
ACE program participation is offered exclusively to academic institutions and provides access to the POAI proprietary active ML/AI and biobank of primary patient dissociated tumor cells (DTCs) at no-cost, with data and IP protection provided to participants. Through this program, investigators or technology transfer offices with potential oncology drug candidates, in the early discovery or development phases, can submit their application to POAI for consideration.
The POAI platform provides data (wet lab and active ML modeling) back to researchers based on access to an otherwise unreachable number of primary patient responses to their drug candidates. This information can improve the probability of technical success and strengthen the data package for the commercialization of submitted compounds.
Applications for inclusion in the ACE program for Q4 2025 will be accepted starting June 15th, 2025.
Interested parties should submit their intention to participate to